Vanguard Group Inc Vaxxinity, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Vaxxinity, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,411,679 shares of VAXX stock, worth $217,051. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,411,679

Previous 2,390,836 0.87%

Holding current value

$217,051

Previous $2.03 Million 14.57%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.62 - $0.86 $12,922 - $17,924	20,843 Added 0.87%	2,411,679 $1.74 Million
Q4 2023 Feb 14, 2024	BUY	$0.7 - $1.31 $9,415 - $17,620	13,451 Added 0.57%	2,390,836 $2.03 Million
Q3 2023 Nov 14, 2023	SELL	$1.25 - $3.0 $8,512 - $20,430	-6,810 Reduced 0.29%	2,377,385 $3.26 Million
Q2 2023 Aug 14, 2023	BUY	$1.73 - $2.79 $389,687 - $628,455	225,253 Added 10.43%	2,384,195 $6.01 Million
Q1 2023 May 15, 2023	BUY	$1.43 - $4.24 $22,343 - $66,250	15,625 Added 0.73%	2,158,942 $4.9 Million

Q4 2022 Feb 10, 2023	SELL	$1.31 - $2.62 $90,218 - $180,436	-68,869 Reduced 3.11%	2,143,317 $3 Million
Q3 2022 Nov 14, 2022	BUY	$1.64 - $2.48 $1.12 Million - $1.69 Million	681,666 Added 44.54%	2,212,186 $4.38 Million
Q2 2022 Aug 12, 2022	BUY	$1.55 - $6.95 $2.29 Million - $10.3 Million	1,475,399 Added 2676.65%	1,530,520 $2.4 Million
Q1 2022 May 13, 2022	SELL	$3.7 - $8.6 $18,052 - $41,959	-4,879 Reduced 8.13%	55,121 $237,000
Q4 2021 Feb 14, 2022	BUY	$5.55 - $18.46 $333,000 - $1.11 Million	60,000 New	60,000 $337,000

Others Institutions Holding VAXX

# of Institutions

Shares Held

12.2M

Call Options Held

Put Options Held

View Full List

About Vaxxinity, Inc.

Ticker VAXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 112,150,000
Market Cap $10.1M
Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...

More about VAXX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Vaxxinity, Inc. Transaction History